Xopenex to have a monopoly?

Only if Sepracor plays its cards right, according to OnThePharm:

In 2008, CFC inhalers are going away, a topic I’ve covered extensively here and here. That leaves Sepracor in a position to make themselves quite a lot of money if they’re willing to do one thing out of the ordinary: price the Xopenex HFA MDI at or below the same price as the other HFA albuterol products. This would set up the PBMs to be receptive to making the product a Tier 2 copay, like most of the racemic albuterol HFA formulations.

Then send out the drug reps.

Related posts:

1. Medi-Cal decides to take albuterol MDIs off formulary
2. Prescription medication pay for performance, and the rationale behind it
3. Are your drug samples spoiled?
4. Does e-prescribing save prescription drug costs?
5. Physicians reporting too few pharmaceutical rep visits
6. TIME.com on the "Pharma Babes"
7. Beware the dangers of universal health care

  Follow on Twitter   Subscribe